rtms - Page 1 | CARLAT PUBLISHING

The Role of rTMS in Poststroke Depression

January 7, 2022

Susan L. Siegfreid, MD Dr. Siegfreid has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Repetitive transcranial magnetic stimulation appears to be a safe and effective treatment for poststroke depression, according to this small study.

TMS Treatment for Depression: An Update

March 11, 2021

Adam Strassberg, MD.

Adam Strassberg, MD. Psychiatrist, private practice. Dr. Strassberg has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Transcranial magnetic stimulation is no longer just for depression, with 6 FDA approvals and 7 different devices to choose from. Adam Strassberg looks at how well this intervention stacks up against ECT and medications. Includes a buyer’s guide to the latest machines.

Getting Uncomfortable with Esketamine

January 13, 2020

Nolan Williams, MD

Nolan Williams, MD

Director of the Brain Stimulation Lab and Interventional Psychiatry Clinical Research Program; Assistant Professor of Psychiatry at Stanford University, CA. Dr. Williams has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The FDA approval of esketamine (Spravalto) left some unanswered questions, including suicide, addiction, withdrawal, neurotoxicity, and bladder inflammation. Nolan Williams addresses those risks and looks at where esketamine fits among other options like TMS and ECT. Dr. Williams directs the Interventional Psychiatry Clinical Research Program and Brain Stimulation Lab at Stanford University.

TMS: Deeper is not Better

January 13, 2020

Edmund S. Higgins, MD.

Edmund S. Higgins, MD. Dr. Higgins has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Two devices are available for transcranial magnetic stimulation (TMS). Neurostar came first with the figure-8 coil, which is now off-patent, while Brainsway’s H-coil which claims to reach deeper into the cerebral cortex. See how they compare in the first head-to-head controlled trial, undertaken without industry support.